Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102

Next Previous
X
Search
Trial Profile

An Open-label Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia) Who Participated in Study IMR-SCD-102

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tovinontrine (Primary) ; Hydroxycarbamide
  • Indications Beta-thalassaemia; Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Enliven Therapeutics; Imara Inc

    • Most Recent Events

    • 23 Feb 2023 According to an Enliven Therapeutics media release, Imara Inc has merged with Enliven Therapeutics. The combined company will operate under the name, Enliven Therapeutics
    • 02 Mar 2022 Status changed from recruiting to active, no longer recruiting.
    • 14 Dec 2021 Results (n=24; data cut-off of 12-May-2021) assessing the long-term safety and benefit of IMR-687 administered to adult subjects with sickle cell disease for up to 4 years, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top